Eva Leinøe

Eva Leinøe

Auto-generated profile, based on publicly available information

Eva Leinøe

Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2020 in Blood
Verified
Journal Article
Open access
PDF file
MSMatthew C. Sims
Matthew C. Sims
LMLouisa Mayer
Louisa Mayer
JCJanine H. Collins
Janine H. Collins
TBTadbir K. Bariana
Tadbir K. Bariana
KMKaryn Megy
Karyn Megy
JGJose A. Guerrero
Jose A. Guerrero
Gray platelet syndrome (GPS) is a rare recessive disorder caused by biallelic variants in NBEAL2 and characterized by bleeding symptoms, the absence of platelet α-granules, splenomegaly, and bone marrow (BM) fibrosis. Due to the rarity of GPS, it has been difficult to fully understand the pathogenic processes that lead to these clinical sequelae. To discern the spectrum of pathologic features, we performed a detailed clinical genotypic and phenotypic study of 47 patients with GPS and identified 32 new etiologic variants in NBEAL2. The GPS patient cohort exhibited known phenotypes, including macrothrombocytopenia, BM fibrosis, megakaryocyte emperipolesis of neutrophils, splenomegaly, and elevated serum vitamin B12 levels. Novel clinical phenotypes were also observed, including reduced leukocyte counts and increased presence of autoimmune disease and positive autoantibodies. There were widespread differences in the transcriptome and proteome of GPS platelets, neutrophils, monocytes, and CD4 lymphocytes. Proteins less abundant in these cells were enriched for constituents of granules, supporting a role for Nbeal2 in the function of these organelles across a wide range of blood cells. Proteomic analysis of GPS plasma showed increased levels of proteins associated with inflammation and immune response. One-quarter of plasma proteins increased in GPS are known to be synthesized outside of hematopoietic cells, predominantly in the liver. In summary, our data show that, in addition to the well-described platelet defects in GPS, there are immune defects. The abnormal immune cells may be the drivers of systemic abnormalities such as autoimmune disease.

27 July 2017 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
ELEva Leinøe
Eva Leinøe
EZEva Zetterberg
Eva Zetterberg
SKSavvas Kinalis
Savvas Kinalis
OØOlga Østrup
Olga Østrup
PKPeter Kampmann
Peter Kampmann
MRMaria Rossing
Maria Rossing
Summary: Rare inherited bleeding disorders (IBD) are a common cause of bleeding tendency. To ensure a correct diagnosis, specialized laboratory analyses are necessary. This study reports the results of an upfront diagnostic strategy using targeted whole exome sequencing. In total, 156 patients with a significant bleeding assessment tool score participated in the study, of which a third had thrombocytopenia. Eighty‐seven genes specifically associated with genetic predisposition to bleeding were analysed by whole exome sequencing. Variants were classified according to the five‐tier scheme. We identified 353 germline variants. Eight patients (5%) harboured a known pathogenic variant. Of the 345 previously unknown variants, computational analyses predicted 99 to be significant. Further filtration according to the Mendelian inheritance pattern, resulted in 59 variants being predicted to be clinically significant. Moreover, 34% (20/59) were assigned as novel class 4 or 5 variants upon targeted functional testing. A class 4 or 5 variant was identified in 30% of patients with thrombocytopenia (14/47) versus 11% of patients with a normal platelet count (12/109) (P < 0·01). An IBD diagnosis has a major clinical impact. The genetic investigations detailed here extricated our patients from a diagnostic conundrum, thus demonstrating that continuous optimization of the diagnostic work‐up of IBD is of great benefit.

13 July 2021 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
KMKaryn Megy
Karyn Megy
KDKate Downes
Kate Downes
MMMarie‐Christine Morel‐Kopp
Marie‐Christine Morel‐Kopp
JBJosé María Bastida
José María Bastida
SBShannon Brooks
Shannon Brooks
KFKathleen Freson
Kathleen Freson
The implementation of High Throughput Sequencing (HTS) technologies in research and diagnostic laboratories has linked many new genes to rare bleeding, thrombotic and platelet disorders (BTPD), and revealed multiple genetic variants linked to those disorders, many of them being of uncertain pathogenicity when considering the accepted evidences (variant consequence, frequency in control datasets, number of reported patients, prediction models, and functional assays). The sequencing effort has also resulted in resources for gathering disease-causing variants associated with specific genes, but for BTPD, such well-curated databases exist only for a few genes. On the other hand, submissions by individuals or diagnostic laboratories to the variant database ClinVar are hampered by the lack of a submission process tailored to capture the specific features of haemostatic diseases. As we move toward the implementation of HTS in the diagnosis of BTPD, the Scientific and Standardization Committee for Genetics in Thrombosis and Haemostasis has developed and tested a REDCap-based interface, aimed at the community, to submit curated genetic variants for diagnostic-grade BTPD genes. Here, we describe the use of the interface and the initial submission of 821 variants from 30 different centers covering 14 countries. This open-access variant resource will be shared with the community to improve variant classification and regular bulk data transfer to ClinVar.

1 February 2005 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
ELEva Birgitte Leinoe
Eva Birgitte Leinoe
MHMarianne Hutchings Hoffmann
Marianne Hutchings Hoffmann
EKErik Kjaersgaard
Erik Kjaersgaard
JNJoern Dalsgaard Nielsen
Joern Dalsgaard Nielsen
OBOlav Jonas Bergmann
Olav Jonas Bergmann
HJHans Erik Johnsen
Hans Erik Johnsen

10 January 2023 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
CZCarlo Zaninetti
Carlo Zaninetti
ELEva Leinøe
Eva Leinøe
MLMaria L Lozano
Maria L Lozano
MRMaria Rossing
Maria Rossing
JBJosé María Bastida
José María Bastida
AGAndreas Greinacher
Andreas Greinacher

1 July 2013 in Leukemia Research
Verified
Journal Article
Closed access
ALAnne Mette Larsen
Anne Mette Larsen
ELEva Birgitte Leinøe
Eva Birgitte Leinøe
PJPär Ingemar Johansson
Pär Ingemar Johansson
HBHenrik Birgens
Henrik Birgens
SOSisse Rye Ostrowski
Sisse Rye Ostrowski